Combined Hemoperfusion and Therapeutic Plasma Exchange for Treatment of Patients With Septic Shock - Trial NCT06404424

Timeline & Enrollment

Primary Outcome

Shock - Free Days

Summary

Sepsis is a critical burden for a healthcare. From 2000 to 2020, the number of publications
 and clinical studies on the topic of Sepsis and septic shock on the National Library of
 Medicine resource The National Center for Biotechnology Information has tripled. Sepsis is a
 life-threatening condition that causes significant pathophysiological changes in the body.
 Currently, sepsis is understood as organ dysfunction caused by a dysregulatory response of
 the macroorganism to infection. A special role in this process belongs to the innate and
 adaptive immune response.
 
 Despite the trend towards improving survival rates, mortality in sepsis remains high - about
 25%, reaching 60% with the development of septic shock.
 
 Extracorporeal therapy, as an adjuvant method of treatment, has been used for more than 30
 years, but conducting large randomized studies confirming its effectiveness is associated
 with a complex of problems, including the extreme heterogeneity of the population of patients
 with sepsis and septic shock, different etiologies and complex pathogenesis, non-identical
 pathophysiological pathways of the dominant organ dysfunction in specific time period and
 degree of its severity.
 
 Goal of the study is to evaluate safety and efficiency of combined hemoperfusion and
 therapeutic plasma exchange in adult patients with septic shock.

ICD-10 Classifications